The pharmaceutical industry marks a major advancement with the FDA approval of Zevantril, a novel medication for the treatment of chronic migraines. Developed by NovaCure Pharmaceuticals, Zevantril is a first-in-class CGRP receptor modulator that has shown significant promise in reducing the frequency and severity of migraines in clinical trials.